A record of what Aditya Khemka said publicly, with the source. Not advice.
Pending — not yet graded
“Cautious on Divi's Lab due to overstretched valuations, trading 40-50% higher than historical averages, despite potential for incremental capex monetization offsetting earnings evaporation from Entresto going generic. The downside appears higher than the upside, leading InCred Asset Management to avoid owning the company.”
Divi's Laboratories LtdBearishCalled 14 Jul 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Aditya Khemka’s full track record